MED18

Across TCGA pan-cancer cohorts, MED18 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MED18 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MED18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED18 expression acts as an unfavorable survival marker.

KIRC are the cancer types where MED18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.123	0.796	<.001	36	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MED18–KIRC (DFS)

Open the KIRC breakdown →